jili178 download apk ENGLAND are set for a Battle of Britain clash with Wales at next year’s Women's Euros, with both drawn in the same group for the contest. The defending champions will face a serious challenge for a knockout stage spot with France and 2017 winners the Netherlands among their rivals. The draw earlier held today in Switzerland, where the tournament will be held next summer, saw England named in Group D alongside contest debutants Wales. Their Welsh opponents sealed qualification via a dramatic play-off defeat of the Republic of Ireland earlier this month. A 3-2 aggregate victory led to them making history by reaching a major women's football tournament for the first time. Wiegman’s England stars, who won the contest two years ago, will begin their push for back-to-back Euros wins by battling on France on July 5. Meanwhile underdogs Wales will face the Netherlands , who won the 2017 tournament under Wiegman four years before the start of her Lionesses reign. And the home nations’ rivals will face off in the final round of Group D fixtures on Sunday July 13 in St Gallen. Yesterday’s draw was preceded by major announcements concerning the contest’s prize pot and balls specially designed to improve VAR use. Prize money for next summer's tournament has more than doubled for the tournament, with the total now standing at £34m - a 156% increase from Euro 2022. Wiegman’s holders will see matches played with chip in ball technology to speed up VAR offside calls. Uefa confirmed it had worked with ball provider Adidas to unveil the most up to date ball product for the Euros. The “KONEKTIS” ball - similar to the one used at last summer’s men’s Euros and by Fifa at the recent World Cups - sends ball data to video officials in real time. Uefa say this can help them determine when the last touch was by an attacking player in tight offside decisions. And with limb-tracking cameras also in operation, VARs are able to come to quicker decisions on potential handball and penalty claims. Should England top their group they could be on course for a difficult path to reach the final. If they finish first, a quarter-final duel with Sweden, or eight-time contest winners Germany could await them on Saturday 19 July. And a mammoth last four clash with Spain could be on the cards, if the latter claims first spot in Group B. The last time the two sides went toe-to-toe was in last year’s World Cup final in Australia with Spain the victors after a 1-0 win. Group A Switzerland, Norway, Iceland, Finland Group B Spain, Portugal, Belgium, Italy Group B Germany, Poland, Denmark, Sweden Group D France, England, Wales, Netherlands

SAN DIEGO and TORONTO, Nov. 25, 2024 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the closing of its previously announced “reasonable best efforts” public offering with participation from the CEO and existing and new healthcare focused investors for the purchase and sale of 40,000,000 common shares at a price of $0.20 per share and warrants to purchase up to 20,000,000 common shares (the “Offering”). The warrants have an exercise price of $0.25 per share, are exercisable immediately and will expire five years from the issuance date. The Company received aggregate gross proceeds of $8 million, before deducting placement agent fees and other offering expenses, and intends to use the net proceeds from this Offering for working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the Offering. The securities described above were offered pursuant to a registration statement on Form S-1 (File No. 333-281201) previously filed with the Securities and Exchange Commission (“SEC”) on August 2, 2024, as amended, which was declared effective on November 21, 2024. This Offering was made only by means of a prospectus forming part of the effective registration statement. A preliminary prospectus relating to the Offering has been filed with the SEC. An electronic copy of the final prospectus relating to the Offering may be obtained on the SEC’s website located at http://www.sec.gov and may also be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at . This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company’s small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company’s lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML), and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit . This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements relating to the intended use of proceeds and statements relating to the Company’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “hope” “should”, “would”, “may”, “potential” and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us, are inherently subject to significant market and other conditions, business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market and economic conditions; unexpected manufacturing defects and other risks detailed from time-to-time in our ongoing current reports, quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. For further information, please contact:

NASCAR insider questions ‘greatness of Richard Petty’ compared to modern era driversBuccaneers Waive LB Antonio Grier

Xavier Clarke to coach Indigenous All Stars team in Perth exhibition clash next February

World peace for now- but till when?Trump offers a public show of support for Pete Hegseth, his embattled nominee to lead the PentagonArticle content PITTSBURGH — The Pittsburgh Penguins acquired centre Philip Tomasino from the Nashville Predators on Monday in exchange for a fourth-round pick in the 2027 draft. Recommended Videos The move gives the struggling Penguins another young player to work with as the franchise tries to emerge from its roughest start in two decades. The 23-year-old Tomasino had one point in 11 games this season for Nashville. The first-round pick in the 2019 draft had 23 goals and 48 assists in 159 games for the Predators since reaching the NHL during the 2021-22 season. The Penguins sent a fourth-rounder that belonged to the New York Rangers to Nashville for Tomasino. Pittsburgh is off to its worst start in nearly two decades. The Penguins are last in the Metropolitan Division and their minus-34 goal differential is the worst in the NHL. While there have been occasional bright spots — star captain Sidney Crosby becoming the latest member of the 600-goal club over the weekend — general manager Kyle Dubas is starting to lean into an overdue youth movement for one of the league’s oldest teams. He sent veteran centre Lars Eller to Washington earlier this month in exchange for multiple draft picks. RECOMMENDED VIDEO

TORONTO (AP) — Prime Minister Justin Trudeau told Donald Trump that Americans would also suffer if the president-elect follows through on a plan to impose sweeping tariffs on Canadian products , a Canadian minister who attended their recent dinner said Monday. Trump threatened to impose tariffs on products from Canada and Mexico if they don’t stop what he called the flow of drugs and migrants across their borders with the United States. He said on social media last week that he would impose a 25% tax on all products entering the U.S. from Canada and Mexico as one of his first executive orders. Canadian Public Safety Minister Dominic LeBlanc, whose responsibilities include border security, attended a dinner with Trump and Trudeau at Trump’s Mar-a-Lago club on Friday. Trudeau requested the meeting in a bid to avoid the tariffs by convincing Trump that the northern border is nothing like the U.S. southern border with Mexico . "The prime minister of course spoke about the importance of protecting the Canadian economy and Canadian workers from tariffs, but we also discussed with our American friends the negative impact that those tariffs could have on their economy, on affordability in the United States as well," LeBlanc said in Parliament. If Trump makes good on his threat to slap 25% tariffs on everything imported from Mexico and Canada, the price increases that could follow will collide with his campaign promise to give American families a break from inflation. Economists say companies would have little choice but to pass along the added costs, dramatically raising prices for food, clothing, automobiles, alcohol and other goods. The Produce Distributors Association, a Washington trade group, said last week that tariffs will raise prices for fresh fruit and vegetables and hurt U.S. farmers when the countries retaliate. Canada is already examining possible retaliatory tariffs on certain items from the U.S. should Trump follow through on the threat. After his dinner with Trump, Trudeau returned home without assurances the president-elect will back away from threatened tariffs on all products from the major American trading partner. Trump called the talks “productive” but signaled no retreat from a pledge that Canada says unfairly lumps it in with Mexico over the flow of drugs and migrants into the United States. “The idea that we came back empty handed is completely false,” LeBlanc said. “We had a very productive discussion with Mr. Trump and his future Cabinet secretaries. ... The commitment from Mr. Trump to continue to work with us was far from empty handed.” Joining Trump and Trudeau at dinner were Howard Lutnick, Trump’s nominee for commerce secretary, North Dakota Gov. Doug Burgum, Trump’s pick to lead the Interior Department, and Mike Waltz, Trump’s choice to be his national security adviser. Canada’s ambassador to the U.S., Kirsten Hillman, told The Associated Press on Sunday that “the message that our border is so vastly different than the Mexican border was really understood.” Hillman, who sat at an adjacent table to Trudeau and Trump, said Canada is not the problem when it comes to drugs and migrants. On Monday, Mexico’s president rejected those comments. “Mexico must be respected, especially by its trading partners,” President Claudia Sheinbaum said. She said Canada had its own problems with fentanyl consumption and “could only wish they had the cultural riches Mexico has.” Flows of migrants and seizures of drugs at the two countries’ border are vastly different. U.S. customs agents seized 43 pounds of fentanyl at the Canadian border during the last fiscal year, compared with 21,100 pounds at the Mexican border. Most of the fentanyl reaching the U.S. — where it causes about 70,000 overdose deaths annually — is made by Mexican drug cartels using precursor chemicals smuggled from Asia. On immigration, the U.S. Border Patrol reported 1.53 million encounters with migrants at the southwest border with Mexico between October 2023 and September 2024. That compares to 23,721 encounters at the Canadian border during that time. Canada is the top export destination for 36 U.S. states. Nearly $3.6 billion Canadian (US$2.7 billion) worth of goods and services cross the border each day. About 60% of U.S. crude oil imports are from Canada, and 85% of U.S. electricity imports as well. Canada is also the largest foreign supplier of steel, aluminum and uranium to the U.S. and has 34 critical minerals and metals that the Pentagon is eager for and investing for national security.